| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgements
|
|
|
|
32 |
S2 |
p. viii
|
artikel
|
| 2 |
Editorial Board
|
|
|
|
32 |
S2 |
p. i
|
artikel
|
| 3 |
Journal Information
|
|
|
|
32 |
S2 |
p. ii
|
artikel
|
| 4 |
LBA3 Atezolizumab with carboplatin as immune induction in metastatic lobular breast cancer: First results of the GELATO-trial
|
Voorwerk, L.
|
|
|
32 |
S2 |
p. S58
|
artikel
|
| 5 |
LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial
|
Bardia, A.
|
|
|
32 |
S2 |
p. S60
|
artikel
|
| 6 |
LBA2 Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab + trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial
|
Graeser, M.
|
|
|
32 |
S2 |
p. S48
|
artikel
|
| 7 |
LBA1 20-year benefit of endocrine therapy in premenopausal breast cancer patients by the 70-gene risk signature
|
Johansson, A.
|
|
|
32 |
S2 |
p. S21
|
artikel
|
| 8 |
96MO A risk analysis of alpelisib (ALP)-induced hyperglycemia (HG) using baseline factors in patients (pts) with advanced solid tumours and breast cancer (BC): A pooled analysis of X2101 and SOLAR-1
|
Rodon, J.
|
|
|
32 |
S2 |
p. S64
|
artikel
|
| 9 |
95MO Characteristics of patients with brain metastases from HER2-positive breast cancer
|
Laakmann, E.
|
|
|
32 |
S2 |
p. S63-S64
|
artikel
|
| 10 |
93MO Overall survival (OS) results by age subgroup from the phase III MONALEESA-7 (ML-7) trial of premenopausal patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
|
Lu, Y-S.
|
|
|
32 |
S2 |
p. S62
|
artikel
|
| 11 |
4MO_PR HER2-low breast cancer: Evolution from primary breast cancer to relapse
|
Miglietta, F.
|
|
|
32 |
S2 |
p. S23
|
artikel
|
| 12 |
94MO Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study
|
Tibau, A.
|
|
|
32 |
S2 |
p. S63
|
artikel
|
| 13 |
Notice and Disclaimer
|
|
|
|
32 |
S2 |
p. iii
|
artikel
|
| 14 |
92O Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
|
Powell, C.A.
|
|
|
32 |
S2 |
p. S61-S62
|
artikel
|
| 15 |
2O Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial
|
Llop-Guevara, A.
|
|
|
32 |
S2 |
p. S22
|
artikel
|
| 16 |
42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)
|
Metzger, O.
|
|
|
32 |
S2 |
p. S37-S38
|
artikel
|
| 17 |
44O Characterization of venous thromboembolic events (VTE), elevated aminotransferases (EAT) and interstitial lung disease (ILD) in monarchE
|
Toi, M.
|
|
|
32 |
S2 |
p. S39-S40
|
artikel
|
| 18 |
1O Detection of homologous recombination repair deficiency (HRD) in treatment-naive early triple-negative breast cancer (TNBC) by RAD51 foci and comparison with DNA-based tests
|
Serra Elizalde, V.
|
|
|
32 |
S2 |
p. S21-S22
|
artikel
|
| 19 |
63O Letrozole and palbociclib versus third generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study
|
Delaloge, S.
|
|
|
32 |
S2 |
p. S48
|
artikel
|
| 20 |
41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial
|
Conte, P.F.
|
|
|
32 |
S2 |
p. S37
|
artikel
|
| 21 |
43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial
|
Dang, C.
|
|
|
32 |
S2 |
p. S38-S39
|
artikel
|
| 22 |
91O Pooled analysis of patient (pt)-reported outcomes (PROs) in the MONALEESA (ML)-2, -3, and -7 trials: Additional results and key subgroup findings
|
Fasching, P.A.
|
|
|
32 |
S2 |
p. S60-S61
|
artikel
|
| 23 |
3O Spatial analysis of lymphocytes and fibroblasts identifies biological relevant patterns in estrogen receptor positive breast cancer
|
Nederlof, I.
|
|
|
32 |
S2 |
p. S22-S23
|
artikel
|
| 24 |
48P Abemaciclib combined with adjuvant endocrine therapy in patients from Asia with high risk early breast cancer: monarchE
|
Yap, Y-S.
|
|
|
32 |
S2 |
p. S41-S42
|
artikel
|
| 25 |
122P Abemaciclib in HR+/HER2- metastatic breast cancer: A real-world experience
|
Bottosso, M.
|
|
|
32 |
S2 |
p. S73-S74
|
artikel
|
| 26 |
11P A Breast Cancer Index (BCI) prognostic model for N0 HR+ breast cancer optimized for late distant recurrence
|
Bartlett, J.M.S.
|
|
|
32 |
S2 |
p. S25
|
artikel
|
| 27 |
138P Absenteeism at work in breast cancer patients undergoing therapy
|
Mejri, N.
|
|
|
32 |
S2 |
p. S81
|
artikel
|
| 28 |
105P A comparative study of cisplatin plus adriamycin compared with cyclophosphamide plus adriamycin in patients with untreated metastatic triple-negative breast cancer (TNBC)
|
Yaqub, S.
|
|
|
32 |
S2 |
p. S68
|
artikel
|
| 29 |
110P Adenoid cystic carcinoma of the breast: A case series of 17 patients and literature review
|
Mery, B.
|
|
|
32 |
S2 |
p. S70
|
artikel
|
| 30 |
19P A dichotomous oncogenic role of the splicing factor SF3A3 in MYC-driven triple-negative breast cancer
|
Bosch, A.
|
|
|
32 |
S2 |
p. S28
|
artikel
|
| 31 |
52P Adjuvant endocrine therapy in HER2-positive breast cancer patients: Systematic review and meta-analysis
|
Peleg Hasson, S.
|
|
|
32 |
S2 |
p. S43
|
artikel
|
| 32 |
78P A dosimetric study of the non-intended irradiation to the internal mammary lymph nodes during locoregional radiotherapy to the breast
|
Yassen, H.
|
|
|
32 |
S2 |
p. S55
|
artikel
|
| 33 |
18P Age-related breast cancer gene expression signature with strong prognostic value
|
Ingebriktsen, L.M.
|
|
|
32 |
S2 |
p. S28
|
artikel
|
| 34 |
68P A meta-analysis of the efficacy of adding immune checkpoint inhibitors to neoadjuvant chemotherapy against triple-negative breast cancer
|
Li, Y.
|
|
|
32 |
S2 |
p. S50-S51
|
artikel
|
| 35 |
99P Analysis of ctDNA in advanced breast cancer reveals polyclonal disease associated with adverse outcome
|
Kingston, B.
|
|
|
32 |
S2 |
p. S65-S66
|
artikel
|
| 36 |
152P Analysis of patient access to breast cancer drugs in the USA and Europe with a focus on the UK and Ireland
|
Mclaughlin, R.A.
|
|
|
32 |
S2 |
p. S86
|
artikel
|
| 37 |
7P An optimized Breast Cancer Index node-positive (BCIN+) prognostic model for late distant recurrence in patients with hormone receptor-positive (HR+) node-positive breast cancer
|
Liefers, G-J.
|
|
|
32 |
S2 |
p. S23-S24
|
artikel
|
| 38 |
39P Applicability of a pathology-based combined model NOLUS (NOn-LUminal Score) in HR+/HER2- early breast cancer patients treated at a tertiary referral center in Mexico
|
Valenzuela-Vidales, A.K.
|
|
|
32 |
S2 |
p. S36
|
artikel
|
| 39 |
31P Association between breast cancer protein truncating variants and febrile neutropenia breast cancer patients treated with taxane or anthracycline chemotherapy in Singapore
|
Ong, S.S.
|
|
|
32 |
S2 |
p. S33
|
artikel
|
| 40 |
139P Association of baseline neutrophil-lymphocyte and platelet-lymphocyte ratios with disease progression in high-risk breast cancer patients
|
Cahyono, R.
|
|
|
32 |
S2 |
p. S81
|
artikel
|
| 41 |
83P Axillary reverse mapping using near-infrared fluorescence imaging in invasive breast cancer (ARMONIC study)
|
Conversano, A.
|
|
|
32 |
S2 |
p. S56
|
artikel
|
| 42 |
21P BACH1 and HIF1α predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC)
|
Vladimirova, V.
|
|
|
32 |
S2 |
p. S29
|
artikel
|
| 43 |
66P Baseline menopausal status, Ki-67 and stromal tumour-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): Exploratory analysis in GeparSixto
|
Labidi-Galy, S.I.
|
|
|
32 |
S2 |
p. S49-S50
|
artikel
|
| 44 |
142P Bone mineral density (BMD) after three years of adjuvant zoledronic acid (ZA) in postmenopausal oestrogen receptor positive (ER+) early breast cancer (EBC): An observational single centre study
|
Harper-Wynne, C.
|
|
|
32 |
S2 |
p. S82
|
artikel
|
| 45 |
9P BRCA1 promoter methylation confers a more favorable prognosis to systemically untreated young triple-negative breast cancer patients than tumour BRCA1 mutation
|
Wang, Y.
|
|
|
32 |
S2 |
p. S24-S25
|
artikel
|
| 46 |
148P Breast cancer as second primary malignancy in cancer survivors: Experience from a Tertiary Cancer Center in India
|
Joseph P, R.
|
|
|
32 |
S2 |
p. S84
|
artikel
|
| 47 |
166P Breast cancer at the age of 90 and above
|
Barinoff, J.
|
|
|
32 |
S2 |
p. S91
|
artikel
|
| 48 |
133P Breast cancer in young women (BCYW): Different entity or different needs?
|
Sánchez, J.C.
|
|
|
32 |
S2 |
p. S79-S80
|
artikel
|
| 49 |
102P Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases: Characteristics and validation of prognostic models in a large real-life database
|
Carausu, M.
|
|
|
32 |
S2 |
p. S67
|
artikel
|
| 50 |
176P Breast cancer treatment during the first wave of the COVID-19 pandemic at a UK centre
|
Balachandran, K.
|
|
|
32 |
S2 |
p. S94
|
artikel
|
| 51 |
174P Breast screening at young age: A real need?
|
Garcia, B. Nunez
|
|
|
32 |
S2 |
p. S93-S94
|
artikel
|
| 52 |
107P CDK4/6i adjustment & tumour response in the COVID-19 era
|
Tippu, Z.
|
|
|
32 |
S2 |
p. S69
|
artikel
|
| 53 |
23P CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): A retrospective analysis of real-world data
|
Martínez-Sáez, O.
|
|
|
32 |
S2 |
p. S30
|
artikel
|
| 54 |
26P Characterization of low HER2 expressions in de-novo metastatic breast cancer
|
Tarantino, P.
|
|
|
32 |
S2 |
p. S31
|
artikel
|
| 55 |
123P Clinical and pathological characteristics of male breast cancer at the Institute for Oncology including first-line treatment in hormone receptor positive tumours
|
Serovic, K.
|
|
|
32 |
S2 |
p. S74
|
artikel
|
| 56 |
104P Clinical characteristics of patients (pts) with complete response (CR) to abemaciclib-based endocrine therapy (ET) in MONARCH 2 (M2) and MONARCH 3 (M3)
|
Huober, J.
|
|
|
32 |
S2 |
p. S67-S68
|
artikel
|
| 57 |
119P Clinical efficacy of everolimus and CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer by treatment sequence
|
Jeong, J.H.
|
|
|
32 |
S2 |
p. S72-S73
|
artikel
|
| 58 |
144P Cognitive complaints among Tunisian breast cancer patients receiving adjuvant aromatase-inhibitors
|
Ben Abdallah, I.
|
|
|
32 |
S2 |
p. S83
|
artikel
|
| 59 |
141P Cognitive impairment among breast cancer patients receiving endocrine treatment: A comparative study between aromatase inhibitors and tamoxifen
|
Ben Abdallah, I.
|
|
|
32 |
S2 |
p. S82
|
artikel
|
| 60 |
165P Comparison of male and female breast cancer in reference hospital in Mexico
|
Sanchez, G.
|
|
|
32 |
S2 |
p. S90-S91
|
artikel
|
| 61 |
13P Comparison study of different programmed death-ligand 1 (PD-L1) assays, readers and scoring methods in triple-negative breast cancer (TNBC)
|
Noske, A.
|
|
|
32 |
S2 |
p. S26
|
artikel
|
| 62 |
24P Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer clinicians: The PROCURE project
|
Curigliano, G.
|
|
|
32 |
S2 |
p. S30-S31
|
artikel
|
| 63 |
58P Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer
|
Guan, X.
|
|
|
32 |
S2 |
p. S45
|
artikel
|
| 64 |
177P COVID-19 pandemic impact in newly diagnosed breast cancer patients (BCP) at a third level hospital
|
Guillen Sacoto, M.C.
|
|
|
32 |
S2 |
p. S95
|
artikel
|
| 65 |
88P CXCR2 small molecule antagonists: A novel approach to enhance the effect of PDL-1 inhibitors in triple-negative breast cancer
|
Ghallab, A.
|
|
|
32 |
S2 |
p. S59
|
artikel
|
| 66 |
168P Danish women favour hypothetical breast cancer screening with harms, but no benefits
|
Røssell, E-L.
|
|
|
32 |
S2 |
p. S91-S92
|
artikel
|
| 67 |
118P Determinants of timing to metastasis in breast cancer patients in Albania
|
Kraja, F.
|
|
|
32 |
S2 |
p. S72
|
artikel
|
| 68 |
179P Discordance rates of clinicopathological features in bilateral breast cancer
|
Aranda-Gutierrez, A.
|
|
|
32 |
S2 |
p. S95-S96
|
artikel
|
| 69 |
160P Distribution of mammographic density and its relationship to age in men
|
Lee, H.
|
|
|
32 |
S2 |
p. S89
|
artikel
|
| 70 |
114P Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer
|
Kristensen, K.B.
|
|
|
32 |
S2 |
p. S71
|
artikel
|
| 71 |
50P Early breast cancer in women aged 35 years or younger: A French population-based case control-matched analysis
|
Dufour, O.
|
|
|
32 |
S2 |
p. S42
|
artikel
|
| 72 |
101P E-cadherin inactivation by Trop-2 drives EMT-less metastatic relapse in triple-negative breast cancer
|
Alberti, S.
|
|
|
32 |
S2 |
p. S66
|
artikel
|
| 73 |
100P Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR+/ER+ breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study
|
Palmieri, C.
|
|
|
32 |
S2 |
p. S66
|
artikel
|
| 74 |
113P Efficacy of oral etoposide associated with trastuzumab in HER2-positive metastatic breast cancer: Results from the Institut Curie’s database
|
Chalumeau, C.
|
|
|
32 |
S2 |
p. S71
|
artikel
|
| 75 |
163P Epidemiological profile of breast cancer in Morocco: First results from the Reference Center for Reproductive Health in Kenitra
|
Aboulhoda, F.
|
|
|
32 |
S2 |
p. S90
|
artikel
|
| 76 |
33P Epigenetic biomarkers ID1, HOXB2 and ATOH8 could predict response to chemotherapy and prognosis in early breast cancer
|
Quiroga Garcia, V.
|
|
|
32 |
S2 |
p. S34
|
artikel
|
| 77 |
108P Epigenetic regulation of the putative breast cancer metastasis suppressor gene SCN4B
|
Hilgers, L.
|
|
|
32 |
S2 |
p. S69
|
artikel
|
| 78 |
87P Epigenetics of the epigenetics: Impact of Let-7a expression restoration in CD8+ cells of HER2+ breast cancer patients
|
Monier, T.
|
|
|
32 |
S2 |
p. S58
|
artikel
|
| 79 |
61P Estimating the cost of adjuvant chemotherapy in ER+/HER2- early breast cancer and distant recurrence of breast cancer in the UK
|
Berdunov, V.
|
|
|
32 |
S2 |
p. S46
|
artikel
|
| 80 |
169P Evaluation of the effectiveness of telephone consultations and the level of satisfaction of patients attending the Unidad Docente Asistencial de Mastología [Mastology Care Teaching Unit] using this method during the COVID health emergency
|
Camejo, N.
|
|
|
32 |
S2 |
p. S92
|
artikel
|
| 81 |
28P EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
|
Leichsenring, J.
|
|
|
32 |
S2 |
p. S32
|
artikel
|
| 82 |
150P Expanding the potential benefits of cognitive behavioural therapy for insomnia in improving psychological functioning and quality of life among breast cancer survivors with insomnia: A meta-analysis of randomized controlled trials
|
Putra, B.P.
|
|
|
32 |
S2 |
p. S85
|
artikel
|
| 83 |
30P Expression signature of Let-7a, miR-34a and miR-486-5p in young triple-negative breast cancer patients overexpressing PDL1: A step towards precision immuno-oncology
|
Kiriacos, C.J.
|
|
|
32 |
S2 |
p. S33
|
artikel
|
| 84 |
180P Factors associated with late-stage diagnosis of breast cancer among Egyptian women
|
Ismail, H.M.
|
|
|
32 |
S2 |
p. S96
|
artikel
|
| 85 |
143P Fertility rates in young breast cancer patients (YBCP) and evolution: A new challenge
|
Mendez Garcia, M.
|
|
|
32 |
S2 |
p. S82-S83
|
artikel
|
| 86 |
98P Final results from AVANTI, a multicentre German observational study of first-line bevacizumab (BEV) + chemotherapy (CT) in >2000 patients (pts) with advanced breast cancer (aBC)
|
Mueller, V.
|
|
|
32 |
S2 |
p. S65
|
artikel
|
| 87 |
46P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study
|
Im, S-A.
|
|
|
32 |
S2 |
p. S40-S41
|
artikel
|
| 88 |
37P Genetic alteration in KLK5 associated with individual mode of breast cancer invasion
|
Novikov, N.
|
|
|
32 |
S2 |
p. S35
|
artikel
|
| 89 |
22P HER2-low vs HER2-zero metastatic breast carcinoma: A clinical and genomic descriptive analysis
|
Sanchez Bayona, R.
|
|
|
32 |
S2 |
p. S29-S30
|
artikel
|
| 90 |
89P High expression of miR-18a drives immunosuppressive activity in ER-positive breast cancer
|
Nair, M.G.
|
|
|
32 |
S2 |
p. S59
|
artikel
|
| 91 |
140P How breast cancer recurrences are found? A real-world, prospective cohort study
|
Myller, S.
|
|
|
32 |
S2 |
p. S81-S82
|
artikel
|
| 92 |
85P Hypofrationated radiotherapy for breast cancer: Does obesity increase the skin toxicity?
|
Ben Amor, R.
|
|
|
32 |
S2 |
p. S57
|
artikel
|
| 93 |
74P Identification of women at high risk of breast cancer who need supplemental screening
|
Czene, K.
|
|
|
32 |
S2 |
p. S54
|
artikel
|
| 94 |
178P Imaging for distant metastasis in local and locally advanced breast cancer: Practice and detection rates
|
Da Silva Oliveira, A.G.
|
|
|
32 |
S2 |
p. S95
|
artikel
|
| 95 |
14P Immunomodulatory effect of denosumab in early breast cancer: Preliminary results of a randomized window-opportunity clinical trial D-Biomark
|
Vethencourt, A.C.
|
|
|
32 |
S2 |
p. S26
|
artikel
|
| 96 |
71P Impact of body mass index (BMI) on pathological complete response (pCR) and survival of breast cancer (BC) patients receiving neoadjuvant chemotherapy (NAC)
|
Aguiar Bujanda, D.
|
|
|
32 |
S2 |
p. S51-S52
|
artikel
|
| 97 |
17P Impact of body mass index (BMI) on prognostic and predictive value of stromal tumour-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): A pooled analysis of six neoadjuvant trials
|
Furlanetto, J.
|
|
|
32 |
S2 |
p. S27-S28
|
artikel
|
| 98 |
146P Impact of breast cancer treatment on sexual health in pre-menopausal women
|
Garg, S.
|
|
|
32 |
S2 |
p. S83-S84
|
artikel
|
| 99 |
154P Impact of COVID-19 on diagnosis and surgical care of patients with breast cancer
|
Lekshmi, A.K.
|
|
|
32 |
S2 |
p. S87
|
artikel
|
| 100 |
151P Impact of germline BRCA (gBRCA) mutation (m) status on clinical characteristics and patterns of care among women with early breast cancer (eBC): An analysis of the observational prospective CANTO cohort
|
Bertaut, A.
|
|
|
32 |
S2 |
p. S86
|
artikel
|
| 101 |
121P Impact of HER2 low (H2L) expression on prognosis in luminal locally advanced or metastatic breast cancer (BC): A retrospective study
|
Saavedra Serrano, C.
|
|
|
32 |
S2 |
p. S73
|
artikel
|
| 102 |
161P Impact of HIV infection on mortality rate and overall survival of women with breast cancer in a Haitian Metterei Cancer Clinic
|
Bernard, J.J.
|
|
|
32 |
S2 |
p. S89-S90
|
artikel
|
| 103 |
53P Incidence of febrile neutropenia (FN), adherence and compliance to granulocyte colony-stimulating factor (G-CSF) on-body injector (OBI) versus other FN prophylaxis in patients receiving myelosuppressive chemotherapy: Subgroup analysis in breast cancer patients
|
Mahtani, R.
|
|
|
32 |
S2 |
p. S43
|
artikel
|
| 104 |
62P Influence of PAM50 on therapeutic decisions in patients with early-stage luminal breast cancer in a single centre
|
Olivares Hernandez, A.
|
|
|
32 |
S2 |
p. S47
|
artikel
|
| 105 |
25P Investigation of TLR4 and pSTAT3 expression on circulating tumour cells (CTCs) in patients with metastatic breast cancer (mBC)
|
Papadaki, M.A.
|
|
|
32 |
S2 |
p. S31
|
artikel
|
| 106 |
97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience
|
Angelis, V.
|
|
|
32 |
S2 |
p. S64-S65
|
artikel
|
| 107 |
20P Is evaluation of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutational status on circulating tumour DNA (ctDNA) by liquid biopsy ready for prime-time? A systematic review and an individual patient meta-analysis
|
Castellana, L.
|
|
|
32 |
S2 |
p. S28-S29
|
artikel
|
| 108 |
81P Is there a benefit for nodal evaluation as part of the post-lumpectomy imaging study before radiotherapy?
|
Pires, A.M.
|
|
|
32 |
S2 |
p. S56
|
artikel
|
| 109 |
45P Long-term efficacy of neratinib in HER2-positive early-stage breast cancer: Overall survival and central nervous system outcomes from the phase III ExteNET trial
|
Chan, A.
|
|
|
32 |
S2 |
p. S40
|
artikel
|
| 110 |
103P Long-term results and bone-protective effect of everolimus added to letrozole and ovarian function suppression for premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated analysis of the LEO study
|
Jeong, H.
|
|
|
32 |
S2 |
p. S67
|
artikel
|
| 111 |
64P Mammographic density to predict response to neoadjuvant chemotherapy for breast cancer
|
Di Cosimo, S.
|
|
|
32 |
S2 |
p. S49
|
artikel
|
| 112 |
172P Men with breast cancer: Biology and stage at diagnosis in Eastern Europe - Balkan Collaborative Project
|
Vasileva-Slaveva, M.B.
|
|
|
32 |
S2 |
p. S93
|
artikel
|
| 113 |
27P MiR-221/222 may enhance epithelial-mesenchymal transition and tamoxifen resistance by down-regulating GATA3
|
Liang, Y-K.
|
|
|
32 |
S2 |
p. S31-S32
|
artikel
|
| 114 |
55P Molecular risk factors for distant metastases in premenopausal patients with HR+/HER2- EBC
|
Ni, H.
|
|
|
32 |
S2 |
p. S44
|
artikel
|
| 115 |
8P Mutational analysis of circulating tumour DNA (ctDNA) in patients with ER+/HER2- advanced breast cancer (ABC) receiving palbociclib (P): Results from the TREnd trial
|
Malorni, L.
|
|
|
32 |
S2 |
p. S24
|
artikel
|
| 116 |
70P Neoadjuvant chemotherapy in breast cancer in the last 2 decades: Are we improving survival? Retrospective analysis in a single institution
|
Ponce, J.
|
|
|
32 |
S2 |
p. S51
|
artikel
|
| 117 |
34P New pathogenic germline mutation in ATM gene in Khakass breast cancer patients
|
Gervas, P.
|
|
|
32 |
S2 |
p. S34
|
artikel
|
| 118 |
159P Obesity and oral contraceptives reduce the preventive benefit of breastfeeding against breast cancer in Mexican women
|
Rodriguez Gutierrez, H.F.
|
|
|
32 |
S2 |
p. S89
|
artikel
|
| 119 |
158P Obstructive sleep apnea and breast cancer incidence: A systematic review and meta-analysis
|
Tan, N.K.W.
|
|
|
32 |
S2 |
p. S89
|
artikel
|
| 120 |
59P Outcomes of women HER2 positive T1a/bN0M0 breast cancer treated with adjuvant trastuzumab: A retrospective population-based cohort study
|
Hendry, J.
|
|
|
32 |
S2 |
p. S45-S46
|
artikel
|
| 121 |
54P Overweight and prognosis in triple-negative breast cancer patients: A systematic review and meta-analysis
|
Harborg, K.S.
|
|
|
32 |
S2 |
p. S43-S44
|
artikel
|
| 122 |
115P Palbociclib-letrozole in advanced breast cancer: A real world review from a regional cancer centre in the United Kingdom
|
Bose, S.
|
|
|
32 |
S2 |
p. S71
|
artikel
|
| 123 |
106P Palbociclib (PAL) in male patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Pt characteristics and treatment (Tx) patterns from the POLARIS study
|
Blum, J.L.
|
|
|
32 |
S2 |
p. S68-S69
|
artikel
|
| 124 |
65P Patient follow-up of NEOVATTL study
|
Vieites, B.
|
|
|
32 |
S2 |
p. S49
|
artikel
|
| 125 |
170P Pattern and prognosis of fatal cardiac events in locoregional and distant stages in female breast cancer patients: SEER- based analysis
|
Safi, M.H.O.
|
|
|
32 |
S2 |
p. S92
|
artikel
|
| 126 |
32P PIK3CA exon 9 and 20 mutations in early luminal breast cancer: Case series and review of the literature
|
Betancor Fernández, I.
|
|
|
32 |
S2 |
p. S33-S34
|
artikel
|
| 127 |
29P Plasma ESR1 mutations and outcome to first-line chemotherapy with bevacizumab and paclitaxel in patients with advanced ER-positive/HER2-negative breast cancer
|
Bos, M.K.
|
|
|
32 |
S2 |
p. S32-S33
|
artikel
|
| 128 |
82P Predicting invasive disease and lymph node involvement in patients with preoperative diagnosis of ductal carcinoma in situ
|
Tondare, A.A.
|
|
|
32 |
S2 |
p. S56
|
artikel
|
| 129 |
117P Pretherapeutic neutrophil-lymphocyte ratio as prognostic and predictive factors in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors
|
Rottier, P.
|
|
|
32 |
S2 |
p. S72
|
artikel
|
| 130 |
153P Prevalence and survival of stage IV male breast cancer: A SEER database analysis
|
Miguel-Semedo, P.
|
|
|
32 |
S2 |
p. S87
|
artikel
|
| 131 |
155P Profile of pathogenic mutations and evaluation of germline genetic testing criteria in consecutive breast cancer patients treated at a North Indian tertiary care center
|
Mittal, A.
|
|
|
32 |
S2 |
p. S87-S88
|
artikel
|
| 132 |
35P Prognostic impact of cytotoxic CD4 T cells (CD4 CTL) in tumour immune microenvironment of breast cancer patients
|
Shohdy, K.S.
|
|
|
32 |
S2 |
p. S34-S35
|
artikel
|
| 133 |
120P Prognostic significance of SAMHD1 expression in breast cancer
|
Margeli Vila, M.
|
|
|
32 |
S2 |
p. S73
|
artikel
|
| 134 |
84P Prospective comparative study of dosimetric parameters and acute radiation toxicity of 3-dimensional conformal radiotherapy (3DCRT) and volumetric modulated arc therapy (VMAT) in post mastectomy carcinoma breast patients
|
Inampudi, P.
|
|
|
32 |
S2 |
p. S57
|
artikel
|
| 135 |
134P_PR Towards tailored follow-up care for breast cancer survivors: Cluster analyses based on symptom burden
|
de Ligt, K.M.
|
|
|
32 |
S2 |
p. S80
|
artikel
|
| 136 |
173P Quality indicators of treatment of breast cancer in Bulgaria
|
Vasileva-Slaveva, M.B.
|
|
|
32 |
S2 |
p. S93
|
artikel
|
| 137 |
157P Racial diversity and reporting in FDA registration trials for breast cancer from 2006 to 2021
|
Lythgoe, M.P.
|
|
|
32 |
S2 |
p. S88
|
artikel
|
| 138 |
80P Radiolabelled trastuzumab Fab as a theranostic molecule for HER2 positive breast cancers
|
Rathore, Y.
|
|
|
32 |
S2 |
p. S55-S56
|
artikel
|
| 139 |
60P Real-life use of Oncotype DX Breast Recurrence Score® test for the management of patients with node-negative and node-positive breast cancer in the autonomous community of Galicia (Spain)
|
Fernandez-Perez, I.
|
|
|
32 |
S2 |
p. S46
|
artikel
|
| 140 |
69P Real world impact of the introduction of targeted axillary dissection (TAD) following neo-adjuvant chemotherapy (NAC)
|
Mohammadi-Zaniani, G.
|
|
|
32 |
S2 |
p. S51
|
artikel
|
| 141 |
111P Real-world outcomes of patients with breast cancer liver metastases treated with transarterial radioembolization: Results from CIRT, a large European prospective multi-centre observational study
|
Arnold, D.
|
|
|
32 |
S2 |
p. S70
|
artikel
|
| 142 |
116P Real-world treatment patterns and clinical effectiveness of eribulin in HR+/HER2- metastatic breast cancer patients in the United States
|
Mougalian, S.S.
|
|
|
32 |
S2 |
p. S72
|
artikel
|
| 143 |
135P Relationship between low muscle mass pre-chemotherapy with hematological toxicity in breast cancer patients after 3 cycles of chemotherapy
|
Kurniawan, A.
|
|
|
32 |
S2 |
p. S80
|
artikel
|
| 144 |
167P Reproductive factors and hormonal contraceptives in relation with breast cancer histopathology
|
Malek, A.B.
|
|
|
32 |
S2 |
p. S91
|
artikel
|
| 145 |
149P Restricted mean survival time (RMST): A new tool for time to event analysis in young breast cancer patients (YBCP)
|
Sánchez, J.C.
|
|
|
32 |
S2 |
p. S84-S85
|
artikel
|
| 146 |
49P Socioeconomic status and survivorship in premenopausal breast cancer patients: A population-based cohort study
|
Hjorth, C.
|
|
|
32 |
S2 |
p. S42
|
artikel
|
| 147 |
109P Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)
|
Laguna, J.C.
|
|
|
32 |
S2 |
p. S69-S70
|
artikel
|
| 148 |
137P Survivorship care plan for breast cancer patients: An intensive follow-up is still useless?
|
Cortesi, G.
|
|
|
32 |
S2 |
p. S81
|
artikel
|
| 149 |
124P Talazoparib in locally advanced or metastatic breast cancer patients: Experience from an early access program in Turkey
|
Sendur, M.A.N.
|
|
|
32 |
S2 |
p. S74
|
artikel
|
| 150 |
79P Targeted intraoperative radiotherapy vs external beam radiotherapy in early-stage breast cancer patients: A systematic review and meta-analysis
|
Hadisurya, A.
|
|
|
32 |
S2 |
p. S55
|
artikel
|
| 151 |
36P The association between tri-nucleotide-repeat containing 9 (TNRC9) /LOC643714 genetic variations and breast cancer in Egyptian females
|
Alhanafy, A.M.
|
|
|
32 |
S2 |
p. S35
|
artikel
|
| 152 |
10P The clinical actionability of PTEN protein and gene expression analysis in HR- and HER2+ breast cancers
|
Fusco, N.
|
|
|
32 |
S2 |
p. S25
|
artikel
|
| 153 |
76P The clinical survival benefit of postmastectomy radiotherapy patients screened form T1-2N1M0 breast cancer according to tumour size and the number of lymph nodes
|
Yang, H.
|
|
|
32 |
S2 |
p. S54
|
artikel
|
| 154 |
15P The combined influence of receptor subtype, grade and TN status on breast cancer survival in recently treated women with non-metastatic disease in Norway
|
Johansson, A.L.
|
|
|
32 |
S2 |
p. S26-S27
|
artikel
|
| 155 |
77P The cost effectiveness and cosmetic outcome of vacuum assisted excision compared to surgical excision for the treatment of benign and high-risk lesions
|
Van De Voort, E.
|
|
|
32 |
S2 |
p. S54-S55
|
artikel
|
| 156 |
51P The development of a predictive model for risk results of the 70-gene signature
|
Slembrouck, L.
|
|
|
32 |
S2 |
p. S42-S43
|
artikel
|
| 157 |
156P The effectiveness of intraoperative administration of both radioactive isotope and blue dye without pre-surgery gamma imaging in comparison with the conventional technique for sentinel node biopsy
|
Vijaykumar, D.K.
|
|
|
32 |
S2 |
p. S88
|
artikel
|
| 158 |
47P The impact of endocrine therapy and chemotherapy on quality of life 5 years after a breast cancer diagnosis: VICAN5 survey
|
Memoli, V.
|
|
|
32 |
S2 |
p. S41
|
artikel
|
| 159 |
86P The impact of the introduction of vacuum assisted excision on clinical management and outcomes of benign and high-risk lesions
|
Van De Voort, E.
|
|
|
32 |
S2 |
p. S57
|
artikel
|
| 160 |
56P The impact of tumour detection method on genomic and clinical risk and chemotherapy recommendation in early hormone receptor positive breast cancer
|
Bar, Y.
|
|
|
32 |
S2 |
p. S44
|
artikel
|
| 161 |
136P The incidence and prognostic impact of obesity in young Egyptian breast cancer patients
|
Athman Omar, A.M.
|
|
|
32 |
S2 |
p. S80-S81
|
artikel
|
| 162 |
57P The level of agreement among medical oncologists on adjuvant chemotherapy decision for breast cancer pre and post Oncotype DX result
|
Alkushi, A.
|
|
|
32 |
S2 |
p. S45
|
artikel
|
| 163 |
145P The potential benefits of internet-based cognitive behavioural therapy for improving psychosocial aspects, sexual functioning, and treatment-induced menopausal symptoms among breast cancer survivors: Systematic review and meta-analysis
|
Putra, B.P.
|
|
|
32 |
S2 |
p. S83
|
artikel
|
| 164 |
132P The psychological impact of the COVID-19 pandemic on patients with early breast cancer
|
Almeida, S.
|
|
|
32 |
S2 |
p. S79
|
artikel
|
| 165 |
12P The RODILIA pilot study for molecular screening of patients with metaplastic breast cancer
|
Silvestri, M.
|
|
|
32 |
S2 |
p. S25-S26
|
artikel
|
| 166 |
67P The role of FDG PET/CT to omit sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer
|
Tanrikulu Simsek, E.
|
|
|
32 |
S2 |
p. S50
|
artikel
|
| 167 |
38P Triple-negative breast cancers with expression of glucocorticoid receptor in immune cells show better prognosis
|
Prabhu, J.S.
|
|
|
32 |
S2 |
p. S35
|
artikel
|
| 168 |
175P Tumour biology in young breast cancer patients (YBCP): A different disease?
|
Cantos Sanchez De Ibarguen, B.
|
|
|
32 |
S2 |
p. S94
|
artikel
|
| 169 |
16P Understanding the biologic determinants of ribociclib efficacy in breast cancer
|
Brasó-Maristany, F.
|
|
|
32 |
S2 |
p. S27
|
artikel
|
| 170 |
162P Unique challenges and outcomes of young breast cancers from a tertiary care cancer centre in India
|
Bajpai, J.
|
|
|
32 |
S2 |
p. S90
|
artikel
|
| 171 |
164P Usefulness of positron emission tomography for determination of axillary metastasis of breast cancer
|
Pösteki, G.
|
|
|
32 |
S2 |
p. S90
|
artikel
|
| 172 |
75P Use of low-dose tamoxifen to improve mammographic screening sensitivity in premenopausal women
|
Eriksson, M.
|
|
|
32 |
S2 |
p. S54
|
artikel
|
| 173 |
171P Validity and reliability tests of the UNS-CASKQ14 questionnaire about the quality and compliance of breast cancer survivors amid the COVID-19 pandemic
|
Soewoto, W.
|
|
|
32 |
S2 |
p. S92-S93
|
artikel
|
| 174 |
147P When a single G-CSF administration is better than longer duration: Example in patients treated by eribulin
|
Schmitt, A.
|
|
|
32 |
S2 |
p. S84
|
artikel
|
| 175 |
112P Women with short survival after diagnosis of metastatic breast cancer: A population-based registry study
|
Boman, C.E.
|
|
|
32 |
S2 |
p. S70-S71
|
artikel
|
| 176 |
6P 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer
|
Dar, H.A.
|
|
|
32 |
S2 |
p. S23
|
artikel
|
| 177 |
Society Pages
|
|
|
|
32 |
S2 |
p. vi-vii
|
artikel
|
| 178 |
Table of Contents
|
|
|
|
32 |
S2 |
p. v
|
artikel
|
| 179 |
128TiP HER2CLIMB-04: Phase II trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ unresectable locally-advanced or metastatic breast cancer with and without brain metastases
|
Hamilton, E.
|
|
|
32 |
S2 |
p. S76
|
artikel
|
| 180 |
126TiP HER2CLIMB-02: Tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
|
Hurvitz, S.A.
|
|
|
32 |
S2 |
p. S75
|
artikel
|
| 181 |
129TiP Metformin (MF) in the prevention of hyperglycemia (HG) in patients (pts) with PIK3CA-mutated, hormone receptor (HR)[+]/HER2[–] advanced breast cancer (ABC) treated with alpelisib (ALP) plus fulvestrant (F): METALLICA
|
Llombart Cussac, A.
|
|
|
32 |
S2 |
p. S77
|
artikel
|
| 182 |
90TiP Monalizumab and trastuzumab in metastatic HER2-positive breast cancer: MIMOSA-trial
|
Geurts, V.C.M.
|
|
|
32 |
S2 |
p. S59
|
artikel
|
| 183 |
127TiP Phase II, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine (CX 2009) in metastatic HR-positive/HER2 non-amplified breast cancer (mHR+/HER2− BC) and CX-2009 as monotherapy and in combination with pacmilimab in metastatic triple-negative breast cancer (mTNBC)
|
Miller, K.D.
|
|
|
32 |
S2 |
p. S76
|
artikel
|
| 184 |
131TiP PRO B: A randomized controlled trial to evaluate the effect of a digital patient-reported outcome monitoring in metastatic breast cancer patients
|
Karsten, M.M.
|
|
|
32 |
S2 |
p. S78
|
artikel
|
| 185 |
72TiP ROSALINE: A phase II, single-arm, neoadjuvant study of targeting ROS1 in combination with endocrine therapy (ET) in invAsive Lobular carcINoma of the brEast
|
Agostinetto, E.
|
|
|
32 |
S2 |
p. S52
|
artikel
|
| 186 |
125TiP SGNTUC-019: Phase II basket study of tucatinib and trastuzumab in previously treated solid tumours with HER2 alterations: HER2-mutated breast cancer cohort
|
Okines, A.
|
|
|
32 |
S2 |
p. S74-S75
|
artikel
|
| 187 |
40TiP SOLTI-1802 ONAWA trial: A window of opportunity trial of onapristone (ONA) in postmenopausal women with estrogen and progesterone receptor-positive/HER2-negative (ER+/PgR+/HER2-) early breast cancer (EBC)
|
Bellet, M.
|
|
|
32 |
S2 |
p. S36
|
artikel
|
| 188 |
130TiP SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype
|
Ciruelos, E.M.
|
|
|
32 |
S2 |
p. S77
|
artikel
|
| 189 |
73TiP SOLTI1710 PROMETEO II: Palbociclib in combination with letrozole in hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)
|
Ciruelos, E.
|
|
|
32 |
S2 |
p. S52-S53
|
artikel
|
| 190 |
Title Page
|
|
|
|
32 |
S2 |
p. iv
|
artikel
|
Tijdschrift beschrijving